<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31801" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>EMS Prehospital Administration Of Thrombolytics For STEMI</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Godfrey</surname>
            <given-names>Andrew</given-names>
          </name>
          <aff>Duke University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Borger</surname>
            <given-names>Judith</given-names>
          </name>
          <aff>Campbell Un. School of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Godfrey declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Judith Borger declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31801.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>ST-segment elevation myocardial infarction (STEMI) is a life-threatening, time-sensitive condition that requires prompt recognition, assessment, and treatment. Percutaneous coronary intervention (PCI) and thrombolysis with intravenous thrombolytics are currently available treatments for the restoration of blood flow to the affected myocardium. Thrombolysis is an available treatment option for prehospital providers; however, given the risks associated with thrombolytics, care must be taken to identify patients who will benefit without undue risk. With the proliferation of PCI facilities and the regionalization of STEMI care, prehospital thrombolysis is generally a viable option where transport times to PCI or emergency department facilities are prolonged. This activity will review the indications, techniques, and requirements surrounding using prehospital thrombolytics for STEMI.</p>
      </sec>
      <sec id="article-31801.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>
<bold>Feasibility and Safety</bold>
</p>
        <p>Multiple studies evaluated prehospital thrombolysis by EMS personnel.<xref ref-type="bibr" rid="article-31801.r1">[1]</xref><xref ref-type="bibr" rid="article-31801.r2">[2]</xref><xref ref-type="bibr" rid="article-31801.r3">[3]</xref>&#x000a0;The American Heart Association (AHA) recommends initiating thrombolytic therapy for patients with ischemic symptoms for less than 12 hours when the time from STEMI identification to PCI is greater than 120 minutes, barring any contraindications to thrombolysis.<xref ref-type="bibr" rid="article-31801.r4">[4]</xref>&#x000a0;In one study in rural North Carolina, Crowder et al. found that prehospital administration of tenecteplase resulted in reperfusion approximately&#x000a0;2 hours sooner than PCI-based strategies and aborted infarction in approximately 25% of cases.<xref ref-type="bibr" rid="article-31801.r5">[5]</xref>&#x000a0;In the same study, 15 (20.5%) patients had serious bleeding, and four patients died (5.5%), similar to prior studies.<xref ref-type="bibr" rid="article-31801.r1">[1]</xref><xref ref-type="bibr" rid="article-31801.r3">[3]</xref>&#x000a0;It merits noting that overall 30-day mortality for STEMI ranges from 2.5% to 10%.<xref ref-type="bibr" rid="article-31801.r6">[6]</xref><xref ref-type="bibr" rid="article-31801.r7">[7]</xref><xref ref-type="bibr" rid="article-31801.r8">[8]</xref></p>
        <p>
<bold>Required Components</bold>
</p>
        <p>The following components are necessary to deliver prehospital thrombolysis for STEMI:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ability to acquire and prehospital 12-lead&#x000a0;electrocardiograms (ECG/EKG)</p>
          </list-item>
          <list-item>
            <p>Ability to transmit 12-lead ECGs to a physician</p>
          </list-item>
          <list-item>
            <p>Reperfusion checklist</p>
          </list-item>
          <list-item>
            <p>Standard STEMI pharmacologic therapy (antiplatelet agents, beta-blockers, nitroglycerin, heparin, etc)</p>
          </list-item>
          <list-item>
            <p>Destination plan</p>
          </list-item>
          <list-item>
            <p>Quality assurance (QA) or quality improvement (QI) plan</p>
          </list-item>
          <list-item>
            <p>Support of all invested parties, including receiving facilities and physicians, community partners, and provider</p>
          </list-item>
        </list>
        <p>Twelve-lead EKG acquisition is a skill commonly taught to paramedics.&#x000a0; Generally, paramedics can interpret 12 lead EKGs to evaluate for STEMI, signs of cardiac ischemia, and rhythm abnormalities. Multiple companies manufacture acquisition devices (including continuous cardiorespiratory monitoring and defibrillation capabilities)&#x000a0; and generally include interpretation software that the purchasing agency can adjust but not the end-user. This software can aid in diagnosing STEMI, and software interpretation may be incorporated into the thrombolysis protocol. While the prehospital interpretation of 12 lead EKGs generally falls to paramedics, the acquisition of 12 lead EKGs may be included in the scope of practice of lower-level providers, including emergency medical technicians (EMTs) and advanced EMTs (AEMTs).</p>
        <p>Generally, physicians must be consulted before administering thrombolytics to help confirm the diagnosis, ensure patient eligibility, and review checklist criteria. As such, the ability to transmit 12-lead EKGs is crucial for real-time analysis by a physician. With the ubiquity of cellular data networks, the ability to transmit 12-lead EKGs is becoming less complex.&#x000a0; Many prehospital cardiac monitors can link wirelessly with a transmitting device such as a smartphone or WiFi hotspot and transmit EKGs directly to a receiving physician. However, rural agencies may not have access to robust late and next-generation cellular networks. Public safety radio networks may be an alternative solution, as well as capturing an image of the EKG printout with a cellular phone and transmitting the image.</p>
        <p>The most feared complication of thrombolysis, whether prehospital or in-hospital, is severe bleeding. Intracranial hemorrhage is perhaps most feared as it can have devastating outcomes and requires immediate recognition and potential intervention. Other complications include severe nonintracranial bleeding such as&#x000a0;gastrointestinal bleeding, allergic reactions including anaphylaxis, reperfusion injury or arrhythmia, and hypotension.<xref ref-type="bibr" rid="article-31801.r9">[9]</xref>&#x000a0;To help minimize the risk of life-threatening bleeding, a reperfusion checklist is necessary before the administration of any thrombolytics. The AHA notes that the following are contraindications to thrombolytic administration<xref ref-type="bibr" rid="article-31801.r4">[4]</xref>:</p>
        <p>
<bold>Absolute contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Any prior intracranial hemorrhage</p>
          </list-item>
          <list-item>
            <p>Known structural cerebral vascular lesion</p>
          </list-item>
          <list-item>
            <p>Known malignant intracranial neoplasm</p>
          </list-item>
          <list-item>
            <p>Ischemic stroke within&#x000a0;2 months&#x000a0;unless acute ischemic stroke within 4.5 hours</p>
          </list-item>
          <list-item>
            <p>High clinical suspicion for aortic dissection</p>
          </list-item>
          <list-item>
            <p>Active bleeding or bleeding disorder other than menses</p>
          </list-item>
          <list-item>
            <p>Significant closed head injury or facial trauma within the last 3 months</p>
          </list-item>
          <list-item>
            <p>Intracranial or spinal surgery in the previous 2 months</p>
          </list-item>
          <list-item>
            <p>Severe, uncontrolled hypertension (systolic blood pressure&#x000a0;[SBP] &#x0003e;180 mmHg or&#x000a0;diastolic blood pressure [DBP] &#x0003e;110 mmHg) unresponsive to pharmacological therapy</p>
          </list-item>
          <list-item>
            <p>Treatment with streptokinase in the previous 6 months</p>
          </list-item>
        </list>
        <p>
<bold>Relative contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>History of poorly controlled, severe, chronic hypertension</p>
          </list-item>
          <list-item>
            <p>Hypertension on presentation (SBP &#x0003e;180 mmHg or DBP greater than 110 mmHg)</p>
          </list-item>
          <list-item>
            <p>History of prior ischemic stroke over 3 months ago</p>
          </list-item>
          <list-item>
            <p>Dementia</p>
          </list-item>
          <list-item>
            <p>Known intracranial pathology not otherwise specified in absolute contraindications</p>
          </list-item>
          <list-item>
            <p>Traumatic CPR or prolonged CPR for greater than 10 minutes</p>
          </list-item>
          <list-item>
            <p>Major surgery within the last 3 weeks</p>
          </list-item>
          <list-item>
            <p>Recent (within 2-4 weeks) internal bleeding</p>
          </list-item>
          <list-item>
            <p>Noncompressible vascular puncture</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Active peptic ulcer</p>
          </list-item>
          <list-item>
            <p>Oral anticoagulant therapy</p>
          </list-item>
        </list>
        <p>Using these contraindications as a guide, an EMS system giving prehospital thrombolytics should develop a reperfusion checklist.</p>
        <p>Adjunctive therapy is a necessary adjunct with thrombolytics; this includes 162 to 324 mg of oral or rectal aspirin, 300 mg of clopidogrel for patients under or equal to 75 years old (75 mg for patients over 75 years old), and heparin (low molecular weight or unfractionated) or fondaparinux.<xref ref-type="bibr" rid="article-31801.r4">[4]</xref>&#x000a0;Nitroglycerin, morphine, and oxygen should also be available for pain relief and treatment of hypoxia. Aspirin, nitroglycerin, morphine, and oxygen are all part of standard prehospital advanced life support therapy for acute coronary syndrome. However, standard&#x000a0;advanced life support units are unlikely to carry clopidogrel, heparin, and fondaparinux.&#x000a0;</p>
        <p>Destination plans require careful evaluation of those systems that implement prehospital thrombolysis. Should thrombolysis fail, the patient may require emergent or urgent PCI for rescue therapy.&#x000a0; Additionally, patients who suffer adverse reactions to thrombolytics may require advanced therapies not available at community or rural hospitals. This therapy may include neurosurgical evaluation and treatment, damage control surgery, advanced heart failure therapy, interventional radiology procedures, or other advanced care. Patients who receive prehospital thrombolytics should preferentially get transported to a PCI facility for further management. In rural situations, this may involve triaging patients who received thrombolytics to be carried by helicopter EMS to a regional facility.</p>
        <p>Prehospital thrombolysis is likely a low-frequency intervention; appropriate quality assurance and quality improvement measures are required to maintain competency and ensure appropriate treatment. This involves evaluating prehospital documentation, including EKGs, and access to patient outcomes and complications. Each case should be reviewed to identify areas of improvement.</p>
        <p>Finally, all members caring for patients receiving prehospital thrombolytics should support a prehospital program. This healthcare team approach includes hospital administrators, EMS administrators and personnel, emergency department physicians, cardiologists, nurses, pharmacists, and regional or referral facilities who may receive prehospital thrombolysis patients when they suffer an adverse event or other less-than-optimal outcomes. All personnel should be involved in the QA/QI process, and regular feedback should be exchanged to optimize a prehospital thrombolysis program. Only with this type of total interprofessional collaboration can a pre&#x02013;intensive care unit&#x000a0;thrombolytic therapy program undergo successful implementation.&#x000a0;</p>
        <p>
<bold>Choice of Thrombolytic Agent</bold>
</p>
        <p>Multiple agents exist to achieve thrombolysis. Streptokinase, a nonfibrin-specific agent, has largely been replaced by newer fibrin-specific agents. Streptokinase is antigenic and can lead to allergic reactions. It has mostly fallen out of favor for systemic thrombolysis in resource-rich settings and is no longer available in the United States. However, it should be a consideration for less resource-rich environments.</p>
        <p>Fibrin-specific agents include tenecteplase (TNK-tPA), reteplase (rPA), and alteplase (tPA). They are not antigenically compared and are generally safer than streptokinase regarding bleeding complications. Tenecteplase can be given as a single IV bolus based on weight, while reteplase requires two boluses 30 minutes apart with fixed dosing. Alteplase is dosed based on weight and requires a 90-minute infusion requiring an IV pump. Tenecteplase is more specific for fibrin, with reteplase and alteplase being less specific. All deliver similar thrombolysis.<xref ref-type="bibr" rid="article-31801.r4">[4]</xref> Alteplase, reteplase, and tenecteplase can be stored at room temperature or refrigerated before&#x000a0;reconstitution. Cost is a significant factor for all thrombolytic agents, and availability and price can play a large part in determining which agent an agency may use. Expired medication is a concern, given that prehospital fibrinolysis may be a low-frequency occurrence.</p>
      </sec>
      <sec id="article-31801.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Prehospital thrombolysis can dramatically reduce the time to restore blood flow to the myocardium suffering from STEMI. The Early Retavase-Thrombolysis In Myocardial Infarction (ER-TIMI) trial demonstrated that STEMI patients receiving fibrinolytic therapy in the prehospital setting received said therapy 32 minutes earlier than similar patients who received said therapy in the hospital.<xref ref-type="bibr" rid="article-31801.r1">[1]</xref> A meta-analysis in 2000 by Morrison et al found that prehospital thrombolysis decreased time to thrombolysis and all-cause hospital mortality.<xref ref-type="bibr" rid="article-31801.r10">[10]</xref>&#x000a0;Similar findings were noted in 2006 by Welsh et al in an urban setting.<xref ref-type="bibr" rid="article-31801.r3">[3]</xref>&#x000a0;A Cochrane review in 2014 supported prehospital thrombolysis. However, it pointed out that most data collection was in relatively resource-rich locations, including the US and Europe.<xref ref-type="bibr" rid="article-31801.r11">[11]</xref>&#x000a0;French investigators noted that patients treated with prehospital thrombolysis had higher 1-year survival than those who received hospital-based thrombolysis or PCI.<xref ref-type="bibr" rid="article-31801.r2">[2]</xref>&#x000a0;While this data is encouraging, it is worth noting that the occurrence of STEMI amenable to prehospital thrombolysis may be relatively infrequent; the Cincinnati Heart Project and the Nashville Prehospital TPA trial found this incidence to be approximately 5%.<xref ref-type="bibr" rid="article-31801.r12">[12]</xref>&#x000a0;As such, the financial implications of implementing a prehospital thrombolysis protocol should be a consideration. However, in a review of the treatment of rural STEMIs in Norway over 11 years, it was noted that prehospital thrombolysis rates increased over time, as did the number of patients receiving PCI within 24 hours. Prehospital thrombolysis was noted to save 131 minutes per patient. Incidents of reperfusion heart failure decreased in that time. Mortality trended downward, and bleeding complications remained stable.<xref ref-type="bibr" rid="article-31801.r13">[13]</xref></p>
        <p>Prehospital thrombolysis can improve STEMI reperfusion times and mortality. Prior to implementing a prehospital thrombolysis program, serious consideration must be given to all available resources, local populations, and QA/QI processes.</p>
      </sec>
      <sec id="article-31801.s4">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31801&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31801">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31801/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31801">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31801.s5">
        <title>References</title>
        <ref id="article-31801.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Antman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Sayah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schuhwerk</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>deLemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Waller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Cutler</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McCabe</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Walls</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2002</year>
            <month>Jul</month>
            <day>03</day>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-7</page-range>
            <pub-id pub-id-type="pmid">12103258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Danchin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Sauval</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hanania</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cambou</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gu&#x000e9;ret</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaur</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boutalbi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gen&#x000e8;s</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lablanche</surname>
                <given-names>JM</given-names>
              </name>
              <collab>USIC 2000 Investigators</collab>
            </person-group>
            <article-title>Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry.</article-title>
            <source>Circulation</source>
            <year>2004</year>
            <month>Oct</month>
            <day>05</day>
            <volume>110</volume>
            <issue>14</issue>
            <fpage>1909</fpage>
            <page-range>1909-15</page-range>
            <pub-id pub-id-type="pmid">15451803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Welsh</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Travers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Senaratne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center.</article-title>
            <source>Am Heart J</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>152</volume>
            <issue>6</issue>
            <fpage>1007</fpage>
            <page-range>1007-14</page-range>
            <pub-id pub-id-type="pmid">17161044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>e362</fpage>
            <page-range>e362-425</page-range>
            <pub-id pub-id-type="pmid">23247304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crowder</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Hubble</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McGinnis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zelman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bozeman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Winslow</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Prehospital administration of tenecteplase for ST-segment elevation myocardial infarction in a rural EMS system.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2011</year>
            <season>Oct-Dec</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-505</page-range>
            <pub-id pub-id-type="pmid">21815730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Messenger</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Cannon</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hewitt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Rumsfeld</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2010</year>
            <month>Jul</month>
            <day>20</day>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>254</fpage>
            <page-range>254-63</page-range>
            <pub-id pub-id-type="pmid">20633817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosamond</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Chambless</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Heiss</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mosley</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Coresh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Whitsel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wagenknecht</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Folsom</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987-2008.</article-title>
            <source>Circulation</source>
            <year>2012</year>
            <month>Apr</month>
            <day>17</day>
            <volume>125</volume>
            <issue>15</issue>
            <fpage>1848</fpage>
            <page-range>1848-57</page-range>
            <pub-id pub-id-type="pmid">22420957</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jernberg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Johanson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Svennblad</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lindb&#x000e4;ck</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wallentin</surname>
                <given-names>L</given-names>
              </name>
              <collab>SWEDEHEART/RIKS-HIA</collab>
            </person-group>
            <article-title>Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.</article-title>
            <source>JAMA</source>
            <year>2011</year>
            <month>Apr</month>
            <day>27</day>
            <volume>305</volume>
            <issue>16</issue>
            <fpage>1677</fpage>
            <page-range>1677-84</page-range>
            <pub-id pub-id-type="pmid">21521849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Califf</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Fortin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Tenaglia</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Sane</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Clinical risks of thrombolytic therapy.</article-title>
            <source>Am J Cardiol</source>
            <year>1992</year>
            <month>Jan</month>
            <day>03</day>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>12A</fpage>
            <page-range>12A-20A</page-range>
            <pub-id pub-id-type="pmid">1729875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morrison</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Verbeek</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Sawadsky</surname>
                <given-names>BV</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis.</article-title>
            <source>JAMA</source>
            <year>2000</year>
            <month>May</month>
            <day>24-31</day>
            <volume>283</volume>
            <issue>20</issue>
            <fpage>2686</fpage>
            <page-range>2686-92</page-range>
            <pub-id pub-id-type="pmid">10819952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCaul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lourens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kredo</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarction.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Sep</month>
            <day>10</day>
            <volume>2014</volume>
            <issue>9</issue>
            <fpage>CD010191</fpage>
            <pub-id pub-id-type="pmid">25208209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibler</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Kereiakes</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Abbottsmith</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Blanton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blanton</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gibler</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial.</article-title>
            <source>Am Heart J</source>
            <year>1991</year>
            <month>Jan</month>
            <volume>121</volume>
            <issue>1 Pt 1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">1898678</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31801.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mannsverk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steigen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tande</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Dahle</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Nedrejord</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hokland</surname>
                <given-names>IO</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Trends in clinical outcomes and survival following prehospital thrombolytic therapy given by ambulance clinicians for ST-elevation myocardial infarction in rural sub-arctic Norway.</article-title>
            <source>Eur Heart J Acute Cardiovasc Care</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">29256635</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
